Physician profile
Mayuri J Joshi
NPI 1477084333
$1,247.50
in general payments reported to CMS, 2019-2025
13 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.43 · 2022: $106 · 2023: $649 · 2024: $345 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $266.43 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $176.89 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $165.42 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $117.29 | 2021-2024 | |
| Glaxosmithkline, LLC. | $109.89 | 2021-2024 | Shingrix, Arexvy |
| Abbott Laboratories | $91.39 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $88.49 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.93 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $72.90 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $22.73 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.15 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $21.23 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $15.76 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayuri Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.